Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Spinal Diseases: HELP
Articles by Chamaida Plasencia-Rodríguez
Based on 5 articles published since 2008
||||

Between 2008 and 2019, Chamaida Plasencia-Rodriguez wrote the following 5 articles about Spinal Diseases.
 
+ Citations + Abstracts
1 Guideline Recommendations of the Spanish Society of Rheumatology on treatment and use of systemic biological and non-biological therapies in psoriatic arthritis. 2018

Torre Alonso, Juan Carlos / Díaz Del Campo Fontecha, Petra / Almodóvar, Raquel / Cañete, Juan D / Montilla Morales, Carlos / Moreno, Mireia / Plasencia-Rodríguez, Chamaida / Ramírez García, Julio / Queiro, Rubén. ·Unidad de Reumatología, Hospital Monte Naranco y Universidad de Oviedo, Oviedo, España. · Unidad de Investigación, Sociedad Española de Reumatología, Madrid, España. · Unidad de Reumatología, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, España. · Unidad de Artritis, Servicio de Reumatología, Hospital Clínic, Barcelona, España. · Servicio de Reumatología, Hospital Clínico Universitario de Salamanca, Salamanca, España. · Servicio de Reumatología, Parc Taulí Hospital Universitari, Sabadell, Barcelona, España. · Servicio de Reumatología, Hospital Universitario La Paz, IdiPaz, Madrid, España. · Unidad de Artritis, Servicio de Reumatología, IDIBAPS y Hospital Clínic, Barcelona, España. · Sección de Reumatología, Hospital Universitario Central de Asturias, Oviedo, España. Electronic address: rubenque7@yahoo.es. ·Reumatol Clin · Pubmed #29111261.

ABSTRACT: OBJECTIVE: The main purpose of this recommendation statement is to provide clinicians with the best available evidence and the best opinion agreed upon by the panelists for a rational use of synthetic disease modifying antirheumatic drugs (DMARDs) and biologicals in psoriatic arthritis (PsA) patients. The present document also focuses on important aspects in the management of PsA, such as early diagnosis, therapeutic objectives, comorbidities and optimization of treatment. METHODS: The recommendations were agreed by consensus by a panel of 8 expert rheumatologists, previously selected by the Spanish Society of Rheumatology (SER) through an open call. The phases of the work were: identification of key areas for updating the previous consensus, analysis and synthesis of scientific evidence (modified Oxford system, Centre for Evidence-based Medicine, 2009) and formulation of recommendations based on this evidence and by consensus techniques. RESULTS: Seventeen recommendations were issued for the treatment of PsA patients. Six of them were of general nature, ranging from the early diagnosis and treatment to the importance of assessing comorbidities. The other 11 were focused on the indications for DMARDs and biological therapy in the distinct clinical forms of the disease. Likewise, the situation of failure of the first biological is addressed and treatment algorithms and a table with the different biological therapies are also included. CONCLUSIONS: We present the update of SER recommendations for the treatment of PsA with DMARDs and biologics.

2 Review Anti-TNF discontinuation and tapering strategies in patients with axial spondyloarthritis: a systematic literature review. 2016

Navarro-Compán, Victoria / Plasencia-Rodríguez, Chamaida / de Miguel, Eugenio / Balsa, Alejandro / Martín-Mola, Emilio / Seoane-Mato, Daniel / Cañete, Juan D. ·Department of Rheumatology, IdiPaz, University Hospital La Paz, mvictoria.navarroc@gmail.com. · Department of Rheumatology, IdiPaz, University Hospital La Paz. · Research Unit, Spanish Society of Rheumatology, Madrid and. · Department of Rheumatology, Hospital Clinic and IDIBAPS, Barcelona, Spain. ·Rheumatology (Oxford) · Pubmed #26998860.

ABSTRACT: OBJECTIVE: The aim was to evaluate whether anti-TNF discontinuation and tapering strategies are efficacious for maintaining remission or low disease activity (LDA) in patients with axial spondyloarthritis. METHODS: A systematic literature review up to September 2014 was performed using Medline, EMBASE and Cochrane databases. Longitudinal studies evaluating the efficacy of discontinuation/tapering of anti-TNF therapy to maintain clinical response achieved after receiving a standard dose of the same drug were included. The results were grouped according to the type of strategy (discontinuation or tapering) evaluated. RESULTS: Thirteen studies out of 763 retrieved citations were included. Overall, published data are scarce and the level of evidence of the studies is weak. Five studies provided evidence for assessing discontinuation strategy. The frequency of patients developing flare during the follow-up period ranged between 76 and 100%. The median (range) follow-up period was 52 (36-52) weeks and time to flare 16 (6-24) weeks. Additionally, eight studies evaluating tapering strategy were selected. The percentage of patients maintaining LDA or remission was reported in five studies and ranged between 53 and 100%. The remaining three studies reported the mean change in BASDAI and CRP after reducing the anti-TNF dose and did not observe any relevant increase in these parameters. CONCLUSION: Published data indicate that a tapering strategy for anti-TNF therapy is successful in maintaining remission or LDA in most patients with axial spondyloarthritis. However, a discontinuation strategy is not recommended because it leads to flare in most cases. Further studies with an appropriate design covering the whole spectrum of the disease are required to confirm these results.

3 Article Optimal concentration range of golimumab in patients with axial spondyloarthritis. 2018

Martínez-Feito, Ana / Plasencia-Rodriguez, Chamaida / Navarro-Compán, Victoria / Jurado, Teresa / Kneepkens, Eva Linda / Wolbink, Gertjan J / Martín, Sergio / Ruiz Del Agua, Ainhoa / Navarro, Rosaura / Mezcua, Araceli / Jochems, Andrea / Peiteado, Diana / Bonilla, Maria Gema / Balsa, Alejandro / Pascual-Salcedo, Dora. ·Immunology Unit and Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain. amartinezf@salud.madrid.org. · Rheumatology Department and Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain. · Rheumatology Department, La Paz University Hospital, Madrid, Spain. · Immunology Unit and Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain. · Department of Rheumatology, Amsterdam Rheumatology and immunology Centre, Reade, Amsterdam, The Netherlands. · R & D Department, Progenika- Grifols, Derio; Department of Physiology, Faculty of Medicine and Nursery, University of the Basque Country, UPV/EHU, Bilbao, Spain. · R & D Department, Progenika-Grifols, Derio, Spain. · Department of Physiology, Faculty of Medicine and Nursery, University of the Basque Country, UPV/EHU, Bilbao, Spain. · Immunology Unit, La Paz University Hospital, Madrid, Spain. ·Clin Exp Rheumatol · Pubmed #28980904.

ABSTRACT: OBJECTIVES: To investigate the association between serum golimumab (GLM) trough levels, clinical disease activity and treatment response during the first year of therapy in patients with axial spondyloarthritis (axSpA), as well as determining an optimal concentration range of GLM in axSpA. METHODS: This was an observational prospective study including 49 patients with axSpA monitored during 52 weeks (W52). Serum GLM trough levels were measured by capture ELISA and antidrug antibodies by bridging ELISA at baseline, W24 and W52. Disease activity was assessed by the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical improvement by ΔASDAS. The association between serum GLM trough levels and disease activity was assessed using univariable and multivariable regression. In case of drop-out or missing data before W52, the last observation carried forward (LOCF) was performed. ASDAS values and GLM levels at W24 were available for 42 patients and 38 patients at W52. RESULTS: In the univariable analyses, serum GLM trough levels were inversely associated with ASDAS at W24 (n=42, r =-0.445; p<0.01), at W52 (n=38, r=-0.330; p<0.05) and W52LOCF (n=49, r=-0.309; p<0.05). In the multivariable analysis, this significant association remained. Serum trough GLM levels above the 0.7-1.4mg/L range did not contribute to additional clinical improvement. CONCLUSIONS: In patients with axSpA, serum GLM trough levels are associated with disease activity during the first year of treatment. A concentration range of 0.7-1.4mg/L appears to be useful to achieve clinical response to GLM.

4 Article Increased frequency of circulating CD19+CD24hiCD38hi B cells with regulatory capacity in patients with Ankylosing spondylitis (AS) naïve for biological agents. 2017

Bautista-Caro, María-Belén / de Miguel, Eugenio / Peiteado, Diana / Plasencia-Rodríguez, Chamaida / Villalba, Alejandro / Monjo-Henry, Irene / Puig-Kröger, Amaya / Sánchez-Mateos, Paloma / Martín-Mola, Emilio / Miranda-Carús, María-Eugenia. ·Department of Rheumatology, Hospital Universitario La Paz-IdiPAZ, Madrid, Spain. · Laboratorio de Inmuno-Oncología, Hospital General Universitario Gregorio Marañón, Madrid, Spain. ·PLoS One · Pubmed #28683133.

ABSTRACT: Our objective was to study the frequency of circulating CD19+CD24hiCD38hi B cells (Breg) in AS patients. To this end, peripheral blood was drawn from AS patients naïve for TNF blockers (AS/nb) (n = 42) and healthy controls (HC) (n = 42). Six patients donated blood for a second time, 6 months after initiating treatment with anti-TNFα drugs. After isolation by Ficoll-Hypaque, PBMCs were stained with antibodies to CD3, CD4, CD19, CD24, and CD38, and examined by cytometry. For functional studies, total CD19+ B cells were isolated from PBMCs of 3 HC by magnetical sorting. Breg-depleted CD19+ B cells were obtained after CD19+CD24hiCD38hi B cells were removed from total CD19+ cells by cytometry. Total CD19+ B cells or Breg-depleted CD19+ B cells were established in culture and stimulated through their BCR. Secretion of IFNγ was determined by ELISA in culture supernatants. When compared with HC, AS/nb patients demonstrated a significantly increased frequency of Breg cells, which was independent of disease activity. Anti-TNFα drugs induced a significant reduction of circulating Breg numbers, which were no longer elevated after six months of treatment. Functional in vitro studies showed that the secretion of IFNγ was significantly higher in Breg-depleted as compared with total CD19+ B cells, indicating that Breg can downmodulate B cell pro-inflammatory cytokine secretion. In summary, an increased frequency of circulating CD19+CD24hiCD38hi B cells is observed in AS/nb patients, that is not related with disease activity; anti-TNFα drugs are able to downmodulate circulating Breg numbers in AS.

5 Article Decreased frequencies of circulating follicular helper T cell counterparts and plasmablasts in ankylosing spondylitis patients Naïve for TNF blockers. 2014

Bautista-Caro, María-Belén / Arroyo-Villa, Irene / Castillo-Gallego, Concepción / de Miguel, Eugenio / Peiteado, Diana / Plasencia-Rodríguez, Chamaida / Villalba, Alejandro / Sánchez-Mateos, Paloma / Puig-Kröger, Amaya / Martín-Mola, Emilio / Miranda-Carús, María-Eugenia. ·Department of Rheumatology, Hospital Universitario La Paz-IdiPAZ, Madrid, Spain. · Laboratorio de Inmuno-Oncología, Hospital General Universitario Gregorio Marañón, Madrid, Spain. ·PLoS One · Pubmed #25203742.

ABSTRACT: Follicular helper T cells (Tfh), localized in lymphoid organs, promote B cell differentiation and function. Circulating CD4 T cells expressing CXCR5, ICOS and/or PD-1 are counterparts of Tfh. Three subpopulations of circulating CD4+CXCR5+ cells have been described: CXCR3+CCR6- (Tfh-Th1), CXCR3-CCR6+ (Tfh-Th17), and CXCR3-CCR6- (Tfh-Th2). Only Tfh-Th17 and Tfh-Th2 function as B cell helpers. Our objective was to study the frequencies of circulating Tfh (cTfh), cTfh subsets and plasmablasts (CD19+CD20-CD27+CD38high cells), and the function of cTfh cells, in patients with Ankylosing Spondylitis (AS). To this end, peripheral blood was drawn from healthy controls (HC) (n = 50), AS patients naïve for TNF blockers (AS/nb) (n = 25) and AS patients treated with TNF blockers (AS/b) (n = 25). The frequencies of cTfh and plasmablasts were determined by flow cytometry. Cocultures of magnetically sorted CD4+CXCR5+ T cells with autologous CD19+CD27- naïve B cells were established from 3 AS/nb patients and 3 HC, and concentrations of IgG, A and M were measured in supernatants. We obseved that AS/nb but not AS/b patients, demonstrated decreased frequencies of circulating CD4+CXCR5+ICOS+PD-1+ cells and plasmablasts, together with a decreased (Tfh-Th17+Tfh-Th2)/Tfh-Th1 ratio. The amounts of IgG and IgA produced in cocultures of CD4+CXCR5+ T cells with CD19+CD27- B cells of AS/nb patients were significantly lower than observed in cocultures established from HC. In summary, AS/nb but not AS/b patients, demonstrate a decreased frequency of cTfh and plasmablasts, and an underrepresentation of cTfh subsets bearing a B helper phenotype. In addition, peripheral blood CD4+CXCR5+ T cells of AS/nb patients showed a decreased capacity to help B cells ex vivo.